Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR G677A among 594 thrombotic Jordanian patients

Blood Coagulation and Fibrinolysis

Volumn 16, Issue 6, 2005, Pages 417-421

  Eid, Suhair S ^a,b   Shubeilat, Taisir ^a  

^a KING HUSSEIN MEDICAL CENTER   (Jordan)

^b NONE   (Jordan)

Author keywords

Factor V Leiden; MTHFR C677T; Prothrombin G20210A; Thrombophilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN;

ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; DNA ISOLATION; FEMALE; GENE MUTATION; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCREENING; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 24044478750     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000175478.46831.52     Document Type: Article

References (27)

1. Zoller B, Bertsdotte A, Gareia de Frutos P, Duhlback B. Resistance to activated protein C as an additional risk factor in hereditary deficiency of protein S. Blood 1995; 85:3518-3523.
2. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, De Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:46-67.
3. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346:1133-1134.
4. Awidi A, Shannak M, Bseiso A, Kailani M, Kailani MA, Omar N, Anshasi B. High prevalence of factor V Leiden in healthy Jordanian Arabs. Thromb Haemost 1999; 81:582-584.
5. Eid S, Shubilat T, Habahba N, Rihani G. Frequncy of factor V Leiden, prothrombin G20210A, and methyltetrahydrofolate reductase C677T mutations in 200 healthy individuals, and 150 thrombotic Jordanian patients [Abstract]. Pathophysiol Haemost Thromb 2002; 32 (suppl 2): 135.
6. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698-3703.
7. De Moerloose P, Reber G, Perrier A, Perneger T, Bounameaux H. Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism. Br J Haematol 2000; 110:125-129.
8. Rosendaal FR, Doggen CJM, Zivelin A, Arruda VR, Aiach M, Sis Covick DS, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79:706-708.
9. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease:a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1994; 10:111-113.
10. Klojtmans LAJ, Van den Hevvel LP, Boers GHJ, Frosst P, Stevens EMB, Denheeijer M, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58:35-41.
11. Hessner MJ, Luhm RA, Pearson SL, Endean DJ, Friedman KD, Montgomery RR. Prevalence of prothrombin G20210 A, factor V G1691 A (Leiden), and methyltetrahydrofolate reductase (MTHFR) C 677T in seven different populations determined by multiple allele-specific PCR. Thromb Haemost 1999; 81:733-738.
12. Lane DA, Manucci OM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, et al. Inherited thrombophilia: Part I. Thromb Haemost 1996; 76:651-662.
13. Ocal IT, Sadeghi A, Press RD. Risk of venous thrombosis in carriers of a common mutation in the homocysteine regulatory enzyme methylteterahydrofolate reductase. Mol Diagnosis 1997; 2:61-68.
14. Gregg JP, Yamane AJ, Grody WW. Prevalence of Factor V-Leiden mutation in four distinct American ethnic populations. Am J Med Genet 1997; 73:334-336.
15. Herrman FH, Koesling M, Schoeder W, Latman R, Jimenez-Bonilla R, Lopacciuk S, et al. Prevalence of factor V Leiden mutation in various population. Genet Epidemiol 1997; 14:403-411.
16. Pepe G, Rickards O, Camacho V, Brunelli T, Gori Ann, Giusti B, et al. Prevalence of factor V Leiden mutation in Non-European populations. Thromb Haemost 1997; 77:329-331.
17. 7 Taher A, Khalil I, Shamseddine A, El-Ahdab F, Bazarbchi A. High prevalence of factor V Leiden mutation among healthy individuals and patients with deep venous thrombosis in Lebanon. Thromb Haemost 2001; 86:723-724.
18. Ridker PM, Miletich JP, Hennekens CH, Buring JE. 4047 men and women: implications for venous thromboembolism screening [Abstract]. JAMA 1997; 277:1305-1307.
19. Leroyer C, Mercier B, Oger E, Chenu E, Abgrall JF, Ferec C, Moltier D. Prevalence of 20210A allele of the prothrombin gene in venous thromboembolism patients. Thromb Haemost 1998; 80:49-51.
20. Grenewald M, Germowitz A, Beneke H, Guethner C, Gricsshammer M. Coagulation factor II activity determination is not usefull as a screening tool for the G20210A prothrombin gene allele. Thromb Haemost 2000; 84:141-142.
21. Taher A, Khalil I, Abou-Merhi R, Shamseddine A, Bazarbachi A. High prevalence of prothrombin G20210A mutation among patients with deep venous thrombosis in Lebanon. Thromb Haemost 2003; 89:945-946.
22. Helley D, Chafa O, Yaker NL, Reghits A, Fisher AM. Prevalence of prothrombin gene G20210A mutation in thrombophilic and healthy Algerian subjects. Thromb Haemost 1999; 82:1554-1555.
23. Finan RR, Tamin H, Amen G, Sharide HE, Rasid M, Alunen WY. Factor V G1691A and factor II G20210A mutations. Am J Hematol 2002; 71:300-305.
24. Sovza SS, Ferriani RA, Pontes AG, Zago MA, Franco RF. Factor V leiden and factor II G20210A mutations in patients with recurrent abortion. Hum Reprod 1999; 14:2448-2550.
25. Ray JG, Shmorgun D, Chan WS. Common C677T polymorphism of the methyltetrahydrofolate reductase gene and the risk of venous thromboembolism: meta-analysis of 31 studies. Pathophysiol Haemost Thromb 2002; 32:51-58.
26. Brown K, Luddington R, Baglin T. Effect of the MTHFR C677T variant and risk of venous thromboembolism: interaction with factor V Leiden and prothrombin (G20210A) mutations. Br J Haematol 1998; 103:42-44.
27. 506). Arterioscler Thromb Vasc Biol 1997; 17:1662-1666.